Yarrow Bioscience (YARW) EBITDA Margin (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly EBITDA Margin came in at 4437.21% in Q1 2026, up 16129.0% YoY from N/an in Q1 2025, and up 41.17% on a QoQ basis from 7542.0% in Q2 2025.
Yarrow Bioscience (YARW) EBITDA Margin (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of EBITDA Margin data on file, last reported at 4437.21% in Q1 2026.
- Quarterly EBITDA Margin rose 16129.0% year-over-year to 4437.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7105.54% (up 44495.0% YoY) and the FY2025 annual result came in at 5219.12%, up 350828.0% from the prior year.
- EBITDA Margin advanced to 4437.21% in Q1 2026, from 7542.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 4437.21% in Q1 2026 to a low of 27531.03% in Q4 2022.
- A 5-year average of 8709.53% and a median of 6576.98% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 2429074 bps — and 2023, when it soared 1854156 bps.
- Tracing YARW's EBITDA Margin over 5 years: stood at 27531.03% in 2022, then surged by 67 bps to 8989.47% in 2023, then sank by 71 bps to 15385.54% in 2024, then jumped by 51 bps to 7542.0% in 2025, then surged by 41 bps to 4437.21% in 2026.
- The last three EBITDA Margin figures came in at 4437.21% (Q1 2026), 7542.0% (Q2 2025), and 4598.5% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 19.75% |
| 10 | Yarrow Bioscience | 31.22 Mn | 8.30 Mn | - | -3,102.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,102.00% |
| Mar 31, 2026 | -4,437.21% |
| Jun 30, 2025 | -7,542.00% |
| Mar 31, 2025 | -4,598.50% |
| Dec 31, 2024 | -15,385.54% |
| Sep 30, 2024 | -10,819.01% |
| Jun 30, 2024 | -5,250.51% |
| Mar 31, 2024 | -7,380.00% |
| Dec 31, 2023 | -8,989.47% |
| Sep 30, 2023 | -5,468.42% |
| Jun 30, 2023 | -10,318.00% |
| Mar 31, 2023 | -5,875.00% |
| Dec 31, 2022 | -27,531.03% |
| Sep 30, 2022 | -5,588.62% |
| Jun 30, 2022 | -6,576.98% |
| Mar 31, 2022 | -4,882.58% |
| Dec 31, 2021 | -3,240.29% |
| Sep 30, 2021 | -8,095.49% |
| Jun 30, 2021 | -3,234.58% |
| Mar 31, 2021 | -4,242.17% |